JP2024008104A - Composition for alleviation, inhibition, or prevention of getting out of shape due to high-intensity exercise - Google Patents
Composition for alleviation, inhibition, or prevention of getting out of shape due to high-intensity exercise Download PDFInfo
- Publication number
- JP2024008104A JP2024008104A JP2022109673A JP2022109673A JP2024008104A JP 2024008104 A JP2024008104 A JP 2024008104A JP 2022109673 A JP2022109673 A JP 2022109673A JP 2022109673 A JP2022109673 A JP 2022109673A JP 2024008104 A JP2024008104 A JP 2024008104A
- Authority
- JP
- Japan
- Prior art keywords
- physical condition
- composition
- deterioration
- alleviating
- intensity exercise
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 121
- 230000002265 prevention Effects 0.000 title abstract description 3
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 160
- 239000004310 lactic acid Substances 0.000 claims abstract description 80
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 80
- 241000894006 Bacteria Species 0.000 claims abstract description 76
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims abstract description 63
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims abstract description 54
- 208000029549 Muscle injury Diseases 0.000 claims abstract description 12
- 241000894007 species Species 0.000 claims abstract description 7
- 241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 claims abstract 13
- 230000006866 deterioration Effects 0.000 claims description 95
- 239000008280 blood Substances 0.000 claims description 67
- 210000004369 blood Anatomy 0.000 claims description 67
- 230000007423 decrease Effects 0.000 claims description 48
- 210000003205 muscle Anatomy 0.000 claims description 24
- 229920002444 Exopolysaccharide Polymers 0.000 claims description 22
- 235000015140 cultured milk Nutrition 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 230000003247 decreasing effect Effects 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 235000003715 nutritional status Nutrition 0.000 claims description 9
- 208000000112 Myalgia Diseases 0.000 claims description 8
- 235000021107 fermented food Nutrition 0.000 claims description 8
- 208000013465 muscle pain Diseases 0.000 claims description 8
- 206010049565 Muscle fatigue Diseases 0.000 claims description 7
- 201000002481 Myositis Diseases 0.000 claims description 7
- 102000004506 Blood Proteins Human genes 0.000 claims description 6
- 108010017384 Blood Proteins Proteins 0.000 claims description 6
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 6
- 238000000354 decomposition reaction Methods 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 5
- 206010022437 insomnia Diseases 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 abstract description 12
- 229920001282 polysaccharide Polymers 0.000 abstract description 12
- 239000005017 polysaccharide Substances 0.000 abstract description 12
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 54
- 235000013336 milk Nutrition 0.000 description 23
- 239000008267 milk Substances 0.000 description 23
- 210000004080 milk Anatomy 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 235000013618 yogurt Nutrition 0.000 description 21
- 235000013305 food Nutrition 0.000 description 19
- 235000008924 yoghurt drink Nutrition 0.000 description 18
- 102000004420 Creatine Kinase Human genes 0.000 description 17
- 108010042126 Creatine kinase Proteins 0.000 description 17
- 235000020124 milk-based beverage Nutrition 0.000 description 16
- 230000002378 acidificating effect Effects 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 229940024606 amino acid Drugs 0.000 description 15
- 239000000047 product Substances 0.000 description 12
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 9
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 9
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 235000020776 essential amino acid Nutrition 0.000 description 9
- 239000003797 essential amino acid Substances 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- 229960003104 ornithine Drugs 0.000 description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 150000005693 branched-chain amino acids Chemical class 0.000 description 8
- 229930182817 methionine Natural products 0.000 description 8
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 7
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 7
- 241000194020 Streptococcus thermophilus Species 0.000 description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 7
- 235000013477 citrulline Nutrition 0.000 description 7
- 229960002173 citrulline Drugs 0.000 description 7
- 230000037406 food intake Effects 0.000 description 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 7
- 229960005190 phenylalanine Drugs 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
- 239000004474 valine Substances 0.000 description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 6
- 239000004473 Threonine Substances 0.000 description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 6
- 229960000310 isoleucine Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229960002898 threonine Drugs 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
- 235000020185 raw untreated milk Nutrition 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 235000013861 fat-free Nutrition 0.000 description 4
- 230000006371 metabolic abnormality Effects 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000000284 resting effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000021056 liquid food Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000021067 refined food Nutrition 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 230000037354 amino acid metabolism Effects 0.000 description 2
- 230000000386 athletic effect Effects 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000020251 goat milk Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000020121 low-fat milk Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Abstract
Description
本発明は、高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物に関する。 The present invention relates to a composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise.
従前から高等学校や大学などの部活動において学生らは、比較的激しい運動を行っている。また、近年、ランニングや筋力トレーニングのブームにより、一般生活者が比較的激しい運動を行う機会が増えている。人間が激しい運動（過度な運動）を行うと、アミノ酸の代謝異常が生じたり、栄養状態が悪化したりして、筋損傷などの体調不良に陥るおそれがある。このおそれを低減することを目的として、過去に「ラクトバシラス・プランタラムＴＷＫ１０を有効成分とする、運動後炎症を改善するためのプロバイオティクス組成物（特表２０２２－５０８１２５号公報参照）」や、「ラクトバチルスプランタルム亜種プランタルムＰＳ１２８及びその担体を含む組成物（特表２０２２－５１８５６７号公報）」、「ラクトバチルス・ヘルベティカスを含む菌体により乳を発酵して得た発酵乳を有効成分として含む筋肉痛抑制剤（国際公開第２００７／０２３８９６号）」などが提案されている。 For some time now, students in high schools and universities have engaged in relatively strenuous exercise in extracurricular activities. Furthermore, in recent years, with the boom in running and strength training, opportunities for ordinary people to engage in relatively strenuous exercise have increased. When humans engage in strenuous exercise (excessive exercise), it can lead to abnormalities in amino acid metabolism and deterioration of nutritional status, which can lead to muscle damage and other physical conditions. In order to reduce this fear, in the past we have developed a ``probiotic composition for improving post-exercise inflammation containing Lactobacillus plantarum TWK10 as an active ingredient (see Japanese Patent Publication No. 2022-508125)'', "Composition containing Lactobacillus plantarum subspecies Plantarum PS128 and its carrier (Special Publication No. 2022-518567)", "Fermented milk obtained by fermenting milk with bacterial cells containing Lactobacillus helveticus as an active ingredient" A muscle pain suppressant (International Publication No. 2007/023896) has been proposed.
本発明の課題は、筋損傷などの体調不良に陥るおそれを低減することができる新たな組成物を提供することである。 An object of the present invention is to provide a new composition that can reduce the risk of suffering from poor physical condition such as muscle damage.
上記課題を解決するために、本発明者らは、乳酸菌およびその乳酸菌により生成される菌体外多糖（非医薬系物質）に着目し、その高負荷運動による体調の不良化の緩和効果、抑制効果、予防効果について詳細に検討した。そして、その結果として、乳酸菌および菌体外多糖の少なくとも一方を摂取することにより、上述の効果が得られることを見出し、本発明を完成させた。 In order to solve the above problems, the present inventors focused on lactic acid bacteria and exopolysaccharides (non-medicinal substances) produced by the lactic acid bacteria, and focused on the effect of mitigating and suppressing deterioration in physical condition caused by high-intensity exercise. The effectiveness and preventive effects were examined in detail. As a result, they discovered that the above-mentioned effects can be obtained by ingesting at least one of lactic acid bacteria and exopolysaccharides, and have completed the present invention.
すなわち、本発明は、次の通りとなる。
（１）ラクトバチルス ブルガリカスに属する乳酸菌およびその菌体外多糖の少なくとも一方を有効成分とする、高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。なお、ここにいう「高負荷運動」とは、いわゆる比較的激しい運動や過度な運動であって、例えば、（強度が）最大酸素摂取量の６０％以上となる運動や、テストステロンの分泌量が減少する運動、心拍数が（（２２０－年齢）×０．６）（回／分）超となる運動、心拍数が（（２２０－年齢－安静時心拍数）×（０．６）＋安静時心拍数）（回／分）超となる運動などである。また、ここにいう「体調の不良化」には、身体状態の不良化のみならず心理状態の不良化も含まれている。また、同組成物は、ラクトバチルス ブルガリカスに属する乳酸菌やその菌体外多糖のみならずその他の成分を含んでいてもよい。また、ここにいう「組成物」には、流動食、サプリメントおよび食品添加剤等の製剤、飲食品（動植物そのものを除く。）ならびに飲食品組成物（加工された飲食品を含む。）等の動物（ヒトを含む）が摂取し得る物が含まれる。
That is, the present invention is as follows.
(1) A composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise, which contains at least one of lactic acid bacteria belonging to Lactobacillus bulgaricus and its extracellular polysaccharide as an active ingredient. Note that "high-intensity exercise" here refers to so-called relatively intense or excessive exercise, such as exercise (intensity) that exceeds 60% of maximum oxygen intake, or exercise that increases testosterone secretion. Exercise that decreases heart rate, exercise that causes heart rate to exceed ((220 - age) x 0.6) (times/min), heart rate that increases ((220 - age - resting heart rate) x (0.6) + rest This includes exercise that causes the heart rate to exceed 1 hour (heart rate) (beats/minute). Furthermore, the term "deterioration in physical condition" as used herein includes not only deterioration in physical condition but also deterioration in psychological condition. Further, the composition may contain not only lactic acid bacteria belonging to Lactobacillus bulgaricus and its extracellular polysaccharide, but also other components. In addition, "compositions" as used herein include preparations such as liquid foods, supplements and food additives, food and drink products (excluding animals and plants themselves), food and drink compositions (including processed food and drink products), etc. Includes substances that can be ingested by animals (including humans).
（２）体調の不良化は、身体状態の不良化である、（１）に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 (2) The composition for alleviating, suppressing, or preventing deterioration in physical condition due to high-intensity exercise according to (1), wherein deterioration in physical condition is deterioration in physical condition.
（３）身体状態の不良化は、栄養状態の不良化である、（２）に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 (3) The composition for alleviating, suppressing, or preventing deterioration in physical condition due to high-intensity exercise according to (2), wherein the deterioration in physical condition is deterioration in nutritional status.
（４）栄養状態の不良化は、血中のタンパク質濃度の低下および血中のアミノ酸濃度の低下の少なくとも一方である、（３）に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 (4) Poor nutritional status is at least one of a decrease in protein concentration in the blood and a decrease in amino acid concentration in the blood, and for alleviating or suppressing deterioration in physical condition due to high-intensity exercise described in (3). or prophylactic compositions.
（５）身体状態の不良化は、筋肉量の減少、筋力の低下、筋肉分解、筋疲労、筋炎、筋肉痛および筋損傷の少なくとも一つである、（２）に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 (5) Poor physical condition is at least one of the following: decrease in muscle mass, decrease in muscle strength, muscle decomposition, muscle fatigue, myositis, muscle pain, and muscle damage, and physical condition due to high-intensity exercise described in (2) A composition for alleviating, suppressing or preventing deterioration of.
（６）体調の不良化は、心理状態の不良化である、（１）に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 (6) The composition for alleviating, suppressing, or preventing deterioration in physical condition due to high-intensity exercise according to (1), wherein deterioration in physical condition is deterioration in psychological state.
（７）心理状態の不良化は、不眠、集中力の低下およびうつ病の発症の少なくとも一つである、（６）に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 (7) For alleviating, suppressing, or preventing deterioration in physical condition due to high-intensity exercise described in (6), where deterioration in psychological state is at least one of insomnia, decreased concentration, and onset of depression. Composition for use.
（８）ラクトバチルス ブルガリカスに属する乳酸菌は、ラクトバチルス ブルガリカス デルブルエッキー種に属する乳酸菌である、（１）から（７）のいずれか１つに記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。
（９）ラクトバチルス ブルガリカス デルブルエッキー種に属する乳酸菌は、ラクトバチルス ブルガリクス 亜種 デルブルエッキーＯＬＬ１０７３Ｒ－１（ＦＥＲＭ ＢＰ－１０７４１）である、（８）に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。
(8) The lactic acid bacteria belonging to Lactobacillus bulgaricus are lactic acid bacteria belonging to the species Lactobacillus bulgaricus delbruecki, which is said to be a lactic acid bacterium belonging to the species Lactobacillus bulgaricus. Palliative, suppressive or prophylactic compositions.
(9) The lactic acid bacterium belonging to the Lactobacillus bulgaricus delbrueckii species is Lactobacillus bulgaricus subspecies delbruecki OLL1073R-1 (FERM BP-10741), which is associated with poor physical condition due to high-intensity exercise described in (8). Compositions for alleviating, suppressing, or preventing oxidation.
（１０）組成物は、発酵食品である、（１）から（９）のいずれか１つに記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 (10) The composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise according to any one of (1) to (9), wherein the composition is a fermented food.
（１１）発酵食品は、発酵乳である、（１０）に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 (11) The composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise according to (10), wherein the fermented food is fermented milk.
（１２）発酵食品は、少なくともラクトバチルス ブルガリカスに属する乳酸菌により発酵されたものである、（９）または（１０）に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 (12) The fermented food is fermented by at least lactic acid bacteria belonging to Lactobacillus bulgaricus, and is used for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise according to (9) or (10). Composition.
（１３）ラクトバチルス ブルガリカスに属する乳酸菌は、ラクトバチルス ブルガリカス デルブルエッキー種に属する乳酸菌である、（１２）に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 (13) The lactic acid bacteria belonging to Lactobacillus bulgaricus is a lactic acid bacterium belonging to the species Lactobacillus bulgaricus delbrueckii, and the composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise according to (12). thing.
（１４）ラクトバチルス ブルガリカス デルブルエッキー種に属する乳酸菌は、ラクトバチルス ブルガリクス 亜種 デルブルエッキーＯＬＬ１０７３Ｒ－１（ＦＥＲＭ ＢＰ－１０７４１）である、（１３）に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 (14) The lactic acid bacterium belonging to the Lactobacillus bulgaricus delbrueckii species is Lactobacillus bulgaricus subspecies delbrueckii OLL1073R-1 (FERM BP-10741), which is associated with poor physical condition due to high-intensity exercise described in (13). Compositions for alleviating, suppressing, or preventing oxidation.
（１５）有効成分は発酵乳である、（１）から（７）のいずれか１つに記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 (15) The composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise according to any one of (1) to (7), wherein the active ingredient is fermented milk.
また、本発明には、以下の発明も包含される。
（１６）ラクトバチルス ブルガリカスに属する乳酸菌およびその菌体外多糖の少なくとも一方を含有する組成物を対象に摂取させる、高負荷運動による体調の不良化の緩和、抑制または予防の方法。
The present invention also includes the following inventions.
(16) A method for alleviating, suppressing, or preventing deterioration in physical condition due to high-intensity exercise, which comprises ingesting a composition containing at least one of lactic acid bacteria belonging to Lactobacillus bulgaricus and its extracellular polysaccharide.
（１７）ラクトバチルス ブルガリカスに属する乳酸菌およびその菌体外多糖の少なくとも一方を対象に投与することにより高負荷運動による体調の不良化を緩和、抑制または予防する方法。 (17) A method for alleviating, suppressing, or preventing deterioration in physical condition due to high-intensity exercise by administering to a subject at least one of lactic acid bacteria belonging to Lactobacillus bulgaricus and its extracellular polysaccharide.
（１８）ラクトバチルス ブルガリカスに属する乳酸菌およびその菌体外多糖の少なくとも一方を高負荷運動による体調の不良化の緩和剤、抑制剤または予防剤として使用する方法。 (18) A method of using at least one of a lactic acid bacterium belonging to Lactobacillus bulgaricus and its exopolysaccharide as an agent for alleviating, suppressing, or preventing physical condition caused by high-intensity exercise.
（１９）高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物の製造のための、ラクトバチルス ブルガリカスに属する乳酸菌およびその菌体外多糖の少なくとも一方の使用。 (19) Use of at least one of a lactic acid bacterium belonging to Lactobacillus bulgaricus and its exopolysaccharide for the production of a composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise.
（２０）高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物の製造における、ラクトバチルス ブルガリカスに属する乳酸菌およびその菌体外多糖の少なくとも一方の使用。 (20) Use of at least one of a lactic acid bacterium belonging to Lactobacillus bulgaricus and its exopolysaccharide in the production of a composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise.
（２１）高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物の製造に使用するための、ラクトバチルス ブルガリカスに属する乳酸菌およびその菌体外多糖の少なくとも一方。 (21) At least one of a lactic acid bacterium belonging to Lactobacillus bulgaricus and its extracellular polysaccharide, for use in the production of a composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise.
（２２）高負荷運動による体調の不良化の緩和剤、抑制剤または予防剤としての使用のための、ラクトバチルス ブルガリカスに属する乳酸菌およびその菌体外多糖の少なくとも一方。 (22) At least one of a lactic acid bacterium belonging to Lactobacillus bulgaricus and its exopolysaccharide for use as an agent for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise.
（２３）ラクトバチルス ブルガリカスに属する乳酸菌に乳原料を供給して、高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物を製造する方法。 (23) A method for producing a composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise by supplying a milk raw material to lactic acid bacteria belonging to Lactobacillus bulgaricus.
本発明によれば、ラクトバチルス ブルガリカスに属する乳酸菌およびその菌体外多糖の少なくとも一方を有効成分とする、筋損傷などの体調不良に陥るおそれを低減することができる新たな組成物を提供する According to the present invention, there is provided a new composition that contains at least one of a lactic acid bacterium belonging to Lactobacillus bulgaricus and its exopolysaccharide as an active ingredient, and is capable of reducing the risk of suffering from poor physical condition such as muscle damage.
本発明の実施の形態に係る高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物（以下「高負荷運動体調不良化緩和等用組成物」と称することがある。）は、ラクトバチルス ブルガリカスに属する乳酸菌およびその菌体外多糖の少なくとも一方を有効成分とする。すなわち、同組成物は、ラクトバチルス ブルガリカスに属する乳酸菌のみを含んでいてもよいし、ラクトバチルス ブルガリカスに属する乳酸菌の菌体外多糖のみを含んでいてもよいし、ラクトバチルス ブルガリカスに属する乳酸菌およびその菌体外多糖の両方を含んでいてもよい。また、同組成物は、ラクトバチルス ブルガリカスに属する乳酸菌のみから成っていてもよいし、ラクトバチルス ブルガリカスに属する乳酸菌の菌体外多糖のみから成っていてもよいし、ラクトバチルス ブルガリカスに属する乳酸菌およびその菌体外多糖のみから成っていてもよい。 The composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise according to an embodiment of the present invention (hereinafter sometimes referred to as "composition for alleviating deterioration of physical condition due to high-intensity exercise") is The active ingredient is at least one of lactic acid bacteria belonging to Lactobacillus bulgaricus and its extracellular polysaccharide. That is, the composition may contain only lactic acid bacteria belonging to Lactobacillus bulgaricus, may contain only exopolysaccharides of lactic acid bacteria belonging to Lactobacillus bulgaricus, or may contain only exopolysaccharides of lactic acid bacteria belonging to Lactobacillus bulgaricus. It may contain both lactic acid bacteria and their extracellular polysaccharides. Further, the composition may consist only of lactic acid bacteria belonging to Lactobacillus bulgaricus, may consist only of exopolysaccharides of lactic acid bacteria belonging to Lactobacillus bulgaricus, or may consist only of exopolysaccharides of lactic acid bacteria belonging to Lactobacillus bulgaricus. It may consist only of lactic acid bacteria and their extracellular polysaccharides.
なお、ラクトバチルス ブルガリカスに属する乳酸菌は、ラクトバチルス ブルガリカス デルブルエッキー種に属する乳酸菌であることが好ましく、ラクトバチルス デルブルエッキー 亜種 ブルガリクス（Lactobacillus delbrueckii subsp. bulgaricus）により生成される菌体外多糖であることがより好ましく、ラクトバチルス デルブルエッキー 亜種 ブルガリクス（Lactobacillus delbrueckii subsp. bulgaricus）OLL1073R-1（寄託番号：FERM BP-10741）であることが特に好ましい。 The lactic acid bacteria belonging to Lactobacillus bulgaricus are preferably lactic acid bacteria belonging to the species Lactobacillus delbrueckii, and bacterial cells produced by Lactobacillus delbrueckii subsp. bulgaricus are preferred. More preferably, it is an exopolysaccharide, and particularly preferably Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (Deposit number: FERM BP-10741).
また、上述の菌体外多糖は、目的の効果を有する限り、特に限定されないが、上述のラクトバチルス ブルガリカスに属する乳酸菌により乳を発酵して生成されるものが好ましい。本発明の実施の形態において用いられる菌体外多糖は、１種でもよく、２種以上の組み合わせであってもよい。この菌体外多糖にはリン酸化多糖が含まれる。また、この菌体外多糖には非リン酸化多糖が含まれてもよい。 Further, the above-mentioned exopolysaccharides are not particularly limited as long as they have the desired effect, but those produced by fermenting milk with lactic acid bacteria belonging to the above-mentioned Lactobacillus bulgaricus are preferred. The exopolysaccharides used in the embodiments of the present invention may be one type or a combination of two or more types. This extracellular polysaccharide includes phosphorylated polysaccharide. Moreover, this exopolysaccharide may include non-phosphorylated polysaccharide.
本発明の実施の形態に係る高負荷運動体調不良化緩和等用組成物は、文字通り、高負荷運動による体調の不良化を緩和したり、抑制したり、予防したりする。なお、ここにいう「高負荷運動」とは、いわゆる比較的激しい運動や過度な運動であって、例えば、（強度が）最大酸素摂取量の６０％以上となる運動や、テストステロンの分泌量が減少する運動、心拍数が（（２２０－年齢）×０．６）（回／分）超となる運動、心拍数が（（２２０－年齢－安静時心拍数）×（０．６）＋安静時心拍数）（回／分）超となる運動などである。なお、最大酸素摂取量が７０％以上となる運動や、心拍数が（２２０－年齢）×０．７（回／分）超となる運動、心拍数が（（２２０－年齢－安静時心拍数）×（０．７）＋安静時心拍数（回／分））超となる運動は、その運動を行う者に対してさらに高い負荷をかけることになるが、本発明の実施の形態に係る高負荷運動体調不良化緩和等用組成物は、このようにさらに高い負荷がかかる運動に対しても有効に機能する。上述のような運動としては、例えば、マラソン（ランニング）、ジョギング、速い泳ぎ、サッカー（フットボール）、ラグビー、縄跳び、体操などが挙げられる。すなわち、本発明の実施の形態に係る高負荷運動体調不良化緩和等用組成物の対象者は、上述の運動をしている者であれば特に制限はなく、例えば、運動部に所属する選手や、アスリート、肉体労働者などが挙げられる。また、ここにいう「体調の不良化」としては、身体状態の不良化のみならず心理状態の不良化も含まれる。すなわち、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、「高負荷運動による身体状態の不良化の緩和用、抑制用または予防用組成物」、「高負荷運動による心理状態の不良化の緩和用、抑制用または予防用組成物」と称することもできる。 The composition for alleviating deterioration of physical condition due to high-intensity exercise according to an embodiment of the present invention literally alleviates, suppresses, or prevents deterioration of physical condition due to high-intensity exercise. Note that "high-intensity exercise" here refers to so-called relatively intense or excessive exercise, such as exercise (intensity) that exceeds 60% of maximum oxygen intake, or exercise that increases testosterone secretion. Exercise that decreases heart rate, exercise that causes heart rate to exceed ((220 - age) x 0.6) (times/min), heart rate that increases ((220 - age - resting heart rate) x (0.6) + rest This includes exercise that causes the heart rate to exceed 1 hour (heart rate) (beats/minute). In addition, exercise that causes maximum oxygen uptake to be 70% or more, exercise that causes heart rate to exceed (220 - age) x 0.7 (times/min), and heart rate ((220 - age - resting heart rate) ) × (0.7) + resting heart rate (times/minute) The composition for alleviating deterioration of physical condition due to high-intensity exercise functions effectively even during such exercise that requires even higher loads. Examples of the above-mentioned exercises include marathon (running), jogging, fast swimming, soccer (football), rugby, rope jumping, and gymnastics. In other words, the subjects of the composition for alleviating deterioration due to high-intensity exercise according to the embodiment of the present invention are not particularly limited as long as they engage in the above-mentioned exercise, and for example, are athletes who belong to an athletic club. , athletes, and manual workers. Moreover, the term "unwell physical condition" as used herein includes not only a deterioration in physical condition but also a deterioration in psychological condition. In other words, the composition for alleviating deterioration of physical condition due to high-intensity exercise according to the present embodiment is a "composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise," and "composition for alleviating deterioration in physical condition due to high-intensity exercise." It can also be referred to as a "composition for alleviating, suppressing, or preventing deterioration of a condition."
身体状態の不良化の一例として、栄養状態の不良化が挙げられる。なお、ここで、栄養状態の不良化としては、例えば、血中タンパク質濃度の低下や、血中アミノ酸濃度の低下などが挙げられる。すなわち、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、「高負荷運動による血中タンパク質濃度低下の緩和用、抑制用または予防用組成物」、「高負荷運動による血中アミノ酸濃度の低下の緩和用、抑制用または予防用組成物」と称することもできる。また、血中アミノ酸濃度の低下は、高負荷運動による体内の代謝異常に起因することが知られている。すなわち、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、「高負荷運動による体内の代謝異常の緩和用、抑制用または予防用組成物」と称することもできる。 An example of poor physical condition is poor nutritional status. Here, examples of poor nutritional status include a decrease in blood protein concentration and a decrease in blood amino acid concentration. That is, the composition for alleviating deterioration of physical condition due to high-intensity exercise according to the present embodiment is a "composition for alleviating, suppressing, or preventing a decrease in blood protein concentration due to high-intensity exercise," and "a composition for reducing blood protein concentration caused by high-intensity exercise." It can also be referred to as ``a composition for alleviating, suppressing, or preventing a decrease in the concentration of amino acids in humans''. Furthermore, it is known that a decrease in blood amino acid concentration is caused by metabolic abnormalities in the body due to high-intensity exercise. That is, the composition for alleviating deterioration caused by high-intensity exercise according to the present embodiment can also be referred to as a "composition for alleviating, suppressing, or preventing metabolic abnormalities in the body caused by high-intensity exercise."
ここにいう「血中タンパク質」としては、例えば、アルブミンやグロブリンなどが挙げられる。 Examples of the "blood protein" here include albumin and globulin.
また、ここにいう「血中アミノ酸」としては、例えば、必須アミノ酸であるイソロイシン，ロイシン，リジン，メチオニン，フェニルアラニン，トレオニン（スレオニン），トリプトファン，バリン，ヒスチジンや、非必須アミノ酸であるチロシン，システイン，アスパラギン酸，アスパラギン，セリン，グルタミン酸，グルタミン，プロリン，グリシン，アラニン，アルギニン、オルニチン、シトルリンが挙げられる。 In addition, the "blood amino acids" mentioned here include, for example, the essential amino acids isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, histidine, and the non-essential amino acids tyrosine, cysteine, Examples include aspartic acid, asparagine, serine, glutamic acid, glutamine, proline, glycine, alanine, arginine, ornithine, and citrulline.
また、身体状態の不良化の別の一例として、筋肉量の減少、筋力の低下、筋肉分解、筋疲労、筋炎、筋肉痛、筋損傷などが挙げられる。すなわち、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、「高負荷運動による筋肉量の減少、筋力の低下、筋肉分解、筋疲労、筋炎、筋肉痛および筋損傷の少なくとも一つの症状の緩和用、抑制用または予防用組成物」と称することもできる。 Further, other examples of poor physical condition include decrease in muscle mass, decrease in muscle strength, muscle decomposition, muscle fatigue, myositis, muscle pain, and muscle damage. In other words, the composition for alleviating deterioration due to high-load exercise according to the present embodiment "at least reduces muscle mass, decrease in muscle strength, muscle decomposition, muscle fatigue, myositis, muscle pain, and muscle damage caused by high-load exercise." It can also be referred to as a "composition for alleviating, suppressing, or preventing one symptom."
なお、本願発明者らの鋭意検討の結果、高負荷運動による上述の症状は、血中のアミノ酸（特に必須アミノ酸、そのなかでもバリンやイソロイシン等の分岐鎖アミノ酸）の濃度の低下に起因すると推察されている。これに対し、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、高負荷運動による血中のバリンやイソロイシンの濃度の低下を緩和、抑制または予防することが確認されている。したがって、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、「高負荷運動による血中バリン濃度低下の緩和用、抑制用または予防用組成物」、「高負荷運動による血中イソロイシン濃度の低下の緩和用、抑制用または予防用組成物」と称することもできる。 As a result of intensive studies by the inventors of the present application, it is assumed that the above-mentioned symptoms caused by high-intensity exercise are caused by a decrease in the concentration of amino acids (particularly essential amino acids, especially branched-chain amino acids such as valine and isoleucine) in the blood. has been done. In contrast, it has been confirmed that the composition for alleviating deterioration of physical condition due to high-intensity exercise according to the present embodiment alleviates, suppresses, or prevents the decrease in blood valine and isoleucine concentrations caused by high-intensity exercise. . Therefore, the composition for alleviating deterioration due to high-intensity exercise according to the present embodiment is a "composition for alleviating, suppressing, or preventing a decrease in blood valine concentration caused by high-intensity exercise," and "composition for reducing blood valine concentration due to high-intensity exercise." It can also be referred to as a "composition for alleviating, suppressing, or preventing a decrease in intermediate isoleucine concentration."
また、本願発明者らにより、高負荷運動により血中のチロシンや、リジン、フェニルアラニン，トレオニン、オルニチン、シトルリンの濃度も低下することが確認されている。これに対し、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、高負荷運動による血中のチロシンや、リジン、フェニルアラニン，トレオニン、オルニチン、シトルリンの濃度の低下を緩和、抑制または予防することが確認されている。したがって、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、「高負荷運動による血中チロシン濃度低下の緩和用、抑制用または予防用組成物」、「高負荷運動による血中リジン濃度の低下の緩和用、抑制用または予防用組成物」、「高負荷運動による血中フェニルアラニン濃度の低下の緩和用、抑制用または予防用組成物」、「高負荷運動による血中トレオニン濃度の低下の緩和用、抑制用または予防用組成物」、「高負荷運動による血中オルニチン濃度上昇の緩和用、抑制用または予防用組成物」、「高負荷運動による血中シトルリン濃度上昇の緩和用、抑制用または予防用組成物」と称することもできる。 Furthermore, the inventors of the present application have confirmed that high-intensity exercise also reduces the concentrations of tyrosine, lysine, phenylalanine, threonine, ornithine, and citrulline in the blood. In contrast, the composition for alleviating deterioration due to high-intensity exercise according to the present embodiment alleviates and suppresses the decrease in blood tyrosine, lysine, phenylalanine, threonine, ornithine, and citrulline concentrations caused by high-intensity exercise. or has been confirmed to be preventive. Therefore, the composition for alleviating deterioration due to high-intensity exercise according to the present embodiment is a "composition for alleviating, suppressing, or preventing a decrease in blood tyrosine concentration due to high-intensity exercise" ``Composition for alleviating, suppressing, or preventing a decrease in blood phenylalanine concentration due to high-intensity exercise''; ``Composition for alleviating, suppressing, or preventing a decrease in blood phenylalanine concentration due to high-intensity exercise''; ``Blood threonine concentration resulting from high-intensity exercise'' ``Composition for alleviating, suppressing, or preventing a decrease in ornithine concentration''; ``Composition for alleviating, suppressing, or preventing an increase in blood citrulline concentration due to high-intensity exercise''; ``Composition for mitigating, suppressing, or preventing an increase in blood citrulline concentration due to high-intensity exercise''; It may also be referred to as a "palliative, suppressive or prophylactic composition".
また、筋肉量の減少、筋力の低下、筋肉分解、筋疲労、筋炎、筋肉痛、筋損傷が生じると、クレアチンキナーゼが筋から漏出して、血中のクレアチンキナーゼ（ＣＫ）の濃度が高まることが知られている。すなわち、血中クレアチンキナーゼ濃度は、筋肉量の減少、筋力の低下、筋肉分解、筋疲労、筋炎、筋肉痛、筋損傷の程度の指標となり得る。これに対し、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、高負荷運動による血中のクレアチンキナーゼの濃度の上昇を緩和、抑制または予防することが確認されている。したがって、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、「高負荷運動による血中クレアチンキナーゼ濃度上昇の緩和用、抑制用または予防用組成物」と称することもできる。 Additionally, when muscle mass decreases, muscle strength decreases, muscle breakdown, muscle fatigue, myositis, muscle pain, or muscle damage occurs, creatine kinase leaks from the muscle, increasing the concentration of creatine kinase (CK) in the blood. It has been known. That is, blood creatine kinase concentration can be an indicator of the degree of decrease in muscle mass, decrease in muscle strength, muscle decomposition, muscle fatigue, myositis, muscle pain, and muscle damage. On the other hand, it has been confirmed that the composition for alleviating deterioration due to high-intensity exercise according to the present embodiment alleviates, suppresses, or prevents the increase in the concentration of creatine kinase in the blood due to high-intensity exercise. Therefore, the composition for alleviating deterioration due to high-intensity exercise according to the present embodiment can also be referred to as a "composition for alleviating, suppressing, or preventing an increase in blood creatine kinase concentration due to high-intensity exercise."
心理状態の不良化としては、例えば、不眠、集中力の低下、うつ病の発症などが挙げられる。すなわち、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、「高負荷運動による不眠、集中力の低下、および、うつ病の少なくとも一つの症状の緩和用、抑制用または予防用組成物」と称することもできる。なお、不眠は、血中メチオニン濃度や血中オルニチン濃度の低下に起因することが示唆されている。これに対し、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、高負荷運動による血中のメチオニンやオルニチンの濃度の低下を緩和、抑制または予防することが確認されている。したがって、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、「高負荷運動による血中メチオニン濃度低下の緩和用、抑制用または予防用組成物」や「高負荷運動による血中オルニチン濃度低下の緩和用、抑制用または予防用組成物」と称することもできる。また、集中力の低下は、血中分岐鎖アミノ酸濃度の低下に起因することが示唆されている。これに対し、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、高負荷運動による血中分岐鎖アミノ酸濃度の低下を緩和、抑制または予防することが確認されている。したがって、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、「高負荷運動による血中分岐鎖アミノ酸濃度低下の緩和用、抑制用または予防用組成物」と称することもできる。なお、うつ病の発症は、血中必須アミノ酸濃度や血中リジン濃度の低下に起因することが示唆されている。これに対し、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、高負荷運動による血中必須アミノ酸濃度や血中リジン濃度の低下を緩和、抑制または予防することが確認されている。したがって、本実施の形態に係る高負荷運動体調不良化緩和等用組成物は、「高負荷運動による血中必須アミノ酸濃度低下の緩和用、抑制用または予防用組成物」や「高負荷運動による血中リジン濃度低下の緩和用、抑制用または予防用組成物」と称することもできる。 Examples of deteriorating psychological conditions include insomnia, decreased concentration, and onset of depression. In other words, the composition for alleviating deterioration due to high-intensity exercise according to the present embodiment is intended to be used for alleviating, suppressing, or preventing at least one symptom of insomnia, decreased concentration, and depression caused by high-intensity exercise. It can also be referred to as a "composition for use". It has been suggested that insomnia is caused by a decrease in blood methionine concentration or blood ornithine concentration. In contrast, it has been confirmed that the composition for alleviating deterioration due to high-intensity exercise according to the present embodiment alleviates, suppresses, or prevents the decrease in blood methionine and ornithine concentrations caused by high-intensity exercise. . Therefore, the composition for alleviating deterioration of physical condition due to high-intensity exercise according to the present embodiment is a "composition for alleviating, suppressing, or preventing a decrease in blood methionine concentration due to high-intensity exercise" and "composition for reducing blood methionine concentration due to high-intensity exercise" It can also be referred to as ``a composition for alleviating, suppressing, or preventing a decrease in intermediate ornithine concentration''. It has also been suggested that the decrease in concentration is caused by a decrease in the concentration of branched chain amino acids in the blood. On the other hand, it has been confirmed that the composition for alleviating deterioration due to high-intensity exercise according to the present embodiment alleviates, suppresses, or prevents the decrease in blood branched-chain amino acid concentration caused by high-intensity exercise. Therefore, the composition for alleviating deterioration due to high-intensity exercise according to the present embodiment can also be referred to as a "composition for alleviating, suppressing, or preventing a decrease in blood branched-chain amino acid concentration due to high-intensity exercise." . It has been suggested that the onset of depression is caused by a decrease in blood essential amino acid concentrations and blood lysine concentrations. In contrast, it has been confirmed that the composition for alleviating deterioration due to high-intensity exercise according to the present embodiment alleviates, suppresses, or prevents the decrease in blood essential amino acid concentration and blood lysine concentration caused by high-intensity exercise. ing. Therefore, the composition for alleviating deterioration due to high-intensity exercise according to the present embodiment is a "composition for alleviating, suppressing, or preventing a decrease in blood essential amino acid concentration caused by high-intensity exercise" It can also be referred to as a "composition for alleviating, suppressing, or preventing a decrease in blood lysine concentration."
また、本実施の形態に係る高負荷運動体調不良化緩和等用組成物の具体的な形態としては、流動食、サプリメントおよび食品添加剤等の製剤、飲食品（動植物そのものを除く。）ならびに飲食品組成物（加工された飲食品を含む。）等の動物（ヒトを含む）が摂取し得る物が挙げられる。これらの中でも飲食品および飲食品組成物が好ましい。また、飲食品および飲食品組成物の中でも発酵食品が好ましく、発酵食品の中でも発酵乳が好ましい。 Further, specific forms of the composition for alleviating deterioration due to high-intensity exercise according to the present embodiment include preparations such as liquid foods, supplements and food additives, food and drink products (excluding animals and plants themselves), and food and drink products. Examples include products that can be ingested by animals (including humans), such as product compositions (including processed food and drinks). Among these, food and drink products and food and drink compositions are preferred. Moreover, fermented foods are preferable among foods and drinks and food and drink compositions, and fermented milk is preferable among fermented foods.
ところで、この組成物を調製する方法としては、例えば、（ａ）ラクトバチルス ブルガリカスに属する乳酸菌を食品等に添加して同組成物とする方法や、（ｂ）ラクトバチルス ブルガリカスに属する乳酸菌を乳培地で培養し、その乳培養物を同組成物とする方法や、（ｃ）前出の乳培養物を乾燥したり濃縮したりしたものを食品等に添加して同組成物とする方法、（ｄ）前出の乳培養物から菌体外多糖を取り出し、その菌体外多糖を同組成物とする方法、（ｅ）ラクトバチルス ブルガリカスに属する乳酸菌を用いて発酵乳を調製し、その発酵乳を同組成物とする方法、（ｆ）前出の発酵乳を食品等に添加して同組成物とする方法などが挙げられる。 By the way, methods for preparing this composition include, for example, (a) a method of adding lactic acid bacteria belonging to Lactobacillus bulgaricus to foods, etc., and (b) a method of preparing the same composition by adding lactic acid bacteria belonging to Lactobacillus bulgaricus. A method of culturing in a milk medium and making the same composition from the milk culture, or (c) a method of adding the dried or concentrated milk culture mentioned above to foods, etc. to make the same composition. (d) A method of extracting the bacterial exopolysaccharide from the milk culture described above and using the bacterial exopolysaccharide as the same composition; (e) preparing fermented milk using lactic acid bacteria belonging to Lactobacillus bulgaricus; Examples include a method in which the fermented milk is made into the same composition, and (f) a method in which the above-mentioned fermented milk is added to foods, etc. to make the same composition.
同組成物が発酵乳として調製される場合、同組成物を飲食品等として手軽に摂取することができる。また、発酵乳は食経験が豊富で安全性が高く、副作用の心配がないため、摂取者は安心して同組成物を摂取することができる。発酵乳の調製方法としては、例えば、「原料乳を殺菌して冷却した後、その原料乳に、上述のラクトバチルス ブルガリカスに属する乳酸菌を含む乳酸菌スターターを添加して、その乳酸菌スターター入り原料乳を所定の乳酸酸度となるような発酵温度と発酵時間で発酵させる方法」が挙げられる。菌体外多糖は、発酵中にラクトバチルス ブルガリカスに属する乳酸菌により生成される。同方法において、乳酸酸度は、例えば、０．６～１．２である。なお、乳酸酸度は０．６～０．８であることが好ましい。また、発酵温度は、例えば、４０～４５℃である。また、発酵時間は、例えば２～１２時間である。なお、発酵時間は３～８時間であることが好ましい。 When the composition is prepared as fermented milk, it can be easily ingested as food or drink. In addition, fermented milk has been eaten for a long time, is highly safe, and has no concerns about side effects, so consumers can ingest the composition with peace of mind. As a method for preparing fermented milk, for example, after sterilizing and cooling the raw milk, the lactic acid bacteria starter containing the above-mentioned lactic acid bacteria belonging to Lactobacillus bulgaricus is added to the raw milk, and the raw milk containing the lactic acid bacteria starter is prepared. A method of fermenting at a fermentation temperature and fermentation time such that a predetermined lactic acid acidity is achieved. Exopolysaccharide is produced by lactic acid bacteria belonging to Lactobacillus bulgaricus during fermentation. In the same method, the acidity of lactic acid is, for example, 0.6 to 1.2. Note that the acidity of lactic acid is preferably 0.6 to 0.8. Further, the fermentation temperature is, for example, 40 to 45°C. Further, the fermentation time is, for example, 2 to 12 hours. Note that the fermentation time is preferably 3 to 8 hours.
本発明における「ラクトバチルス ブルガリカスに属する乳酸菌」とは、分類学的にラクトバチルス ブルガリカスに属する乳酸菌と認定されたものの全ての総称であり、菌種や菌株などで限定されるものではない。なお、ラクトバチルス ブルガリカスに属する乳酸菌はその由来により、植物由来および動物由来のいずれかに分類することもあるが、本発明では植物由来の乳酸菌、動物由来の乳酸菌のいずれも使用することができる。本発明のラクトバチルス ブルガリカスに属する乳酸菌の菌株は、十分な食経験がある発酵乳（例えば、ヨーグルト等）を調製することができるラクトバチルス ブルガリカスに属する乳酸菌に属する１種または２種以上の菌株であることが好ましい。なお、本発明の実施の形態に係るラクトバチルス ブルガリカスに属する乳酸菌は、ラクトバチルス デルブルエッキー、ラクトバチルス デルブルエッキー 亜種 ブルガリクス（Lactobacillus delbrueckii subsp. bulgaricus）に属する乳酸菌であることが好ましく、「ラクトバチルス デルブルエッキー 亜種 ブルガリクス（Lactobacillus delbrueckii subsp. bulgaricus）OLL1073R-1（寄託番号：FERM BP-10741）」であることが特に好ましい。 In the present invention, "lactic acid bacteria belonging to Lactobacillus bulgaricus" is a general term for all lactic acid bacteria that are taxonomically recognized as belonging to Lactobacillus bulgaricus, and is not limited by bacterial species or strains. Note that lactic acid bacteria belonging to Lactobacillus bulgaricus may be classified as either plant-derived or animal-derived depending on their origin, but in the present invention, both plant-derived and animal-derived lactic acid bacteria can be used. . The strain of lactic acid bacteria belonging to Lactobacillus bulgaricus of the present invention is one or more types of lactic acid bacteria belonging to Lactobacillus bulgaricus that can be used to prepare fermented milk (for example, yogurt, etc.) that has sufficient eating experience. Preferably, it is a bacterial strain. The lactic acid bacteria belonging to Lactobacillus bulgaricus according to the embodiment of the present invention are preferably lactic acid bacteria belonging to Lactobacillus delbrueckii, Lactobacillus delbrueckii subsp. bulgaricus, Particularly preferred is "Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (Deposit number: FERM BP-10741)".
また、乳酸菌スターターとして、ストレプトコッカス属乳酸菌またはストレプトコッカス サーモフィラス（Streptococcus thermophilus）をラクトバチルス属乳酸菌と併用することが、生産効率および嗜好性の観点から好ましい。さらに、ラクトバチルス ブルガリカスに属する乳酸菌がラクトバチルス デルブルエッキー 亜種 ブルガリクス（Lactobacillus delbrueckii subsp. bulgaricus）OLL1073R-1（寄託番号：FERM BP-10741）である場合、サーモフィラス菌は特に限定されないが、Streptococcus thermophilus 1131や、Streptococcus thermophilus OLS3059であることがより好ましい。さらに、乳酸菌スターターとしてまたは機能性の付与などを目的として、ラクトバチルス ブルガリカスに属する乳酸菌およびストレプトコッカス属乳酸菌以外の乳酸菌や、ラクトコッカス菌、ビフィズス菌、酵母などの発酵微生物を添加してもよい。 Further, as a lactic acid bacteria starter, it is preferable to use lactic acid bacteria of the genus Streptococcus or Streptococcus thermophilus in combination with lactic acid bacteria of the genus Lactobacillus, from the viewpoint of production efficiency and palatability. Furthermore, if the lactic acid bacterium belonging to Lactobacillus bulgaricus is Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (deposit number: FERM BP-10741), the thermophilus bacteria is not particularly limited; More preferred are Streptococcus thermophilus 1131 and Streptococcus thermophilus OLS3059. Furthermore, lactic acid bacteria other than the lactic acid bacteria belonging to Lactobacillus bulgaricus and the genus Streptococcus, as well as fermentation microorganisms such as Lactococcus bacteria, Bifidobacteria, and yeast, may be added as a lactic acid bacteria starter or for the purpose of imparting functionality.
ここで、「ラクトバチルス デルブルエッキー 亜種 ブルガリクス（Lactobacillus delbrueckii subsp. bulgaricus）OLL1073R-1」は、独立行政法人産業技術総合研究所 特許生物寄託センターに寄託番号 FERM BP-10741（寄託日：２００６年１１月２９日）で寄託されている。また、「Streptococcus thermophilus OLS3059」は、独立行政法人産業技術総合研究所 特許生物寄託センターに寄託番号 FERM BP-10740（寄託日：２００６年１１月２９日）で寄託されている。Streptococcus thermophilus 1131は、株式会社明治製の明治ブルガリアヨーグルト「LB81」から入手することができる。 Here, "Lactobacillus delbrueckii subsp. bulgaricus (Lactobacillus delbrueckii subsp. bulgaricus) OLL1073R-1" has been deposited with the Patent Organism Depositary Center of the National Institute of Advanced Industrial Science and Technology (AIST) with deposit number FERM BP-10741 (deposit date: 2006). It was deposited on November 29, 2013). Furthermore, "Streptococcus thermophilus OLS3059" has been deposited with the Patent Organism Depositary Center of the National Institute of Advanced Industrial Science and Technology under the deposit number FERM BP-10740 (deposit date: November 29, 2006). Streptococcus thermophilus 1131 can be obtained from Meiji Bulgaria Yogurt "LB81" manufactured by Meiji Co., Ltd.
本発明の実施の形態における「発酵乳」とは、乳を発酵させたものをいい、例えば、乳及び乳製品の成分規格等に関する省令（乳等省令）で定義される「発酵乳」、「乳酸菌飲料」、「乳飲料」、「ナチユラルチーズ」等を包含するがこれらに限定されない。例えば、発酵乳は、乳等省令で定義される「発酵乳」、すなわち、生乳、牛乳、特別牛乳、生山羊乳、殺菌山羊乳、生めん羊乳、成分調整牛乳、低脂肪牛乳、無脂肪牛乳および加工乳などの乳またはこれと同等以上の無脂乳固形分を含む乳等を、乳酸菌または酵母で発酵させ、固形状（ハードタイプ）、糊状（ソフトタイプ）または液状（ドリンクタイプ）にしたもの、または、これらを凍結したものをいうが、これに限定されない。本発明の実施の形態に係る発酵乳において、無脂乳固形分の濃度の範囲は、例えば、４．０質量％以上１２．０質量％以下の範囲内であることが好ましく、６．０質量％以上１０．０質量％以下の範囲内であることがより好ましく、７．０質量％以上９．０質量％以下の範囲内であることがさらに好ましい。また、乳脂肪分の濃度は、例えば、０．２質量％以上４．０％質量以下の範囲内であることが好ましく、０．３質量％以上３．０質量％以下の範囲内であることがより好ましく、０．４質量％以上２．０質量％以下の範囲内であることがさらに好ましい。 "Fermented milk" in the embodiment of the present invention refers to fermented milk, such as "fermented milk" defined in the Ministerial Ordinance on Ingredient Standards for Milk and Dairy Products (Ministerial Ordinance on Milk, etc.); Examples include, but are not limited to, "lactic acid bacteria drinks," "milk drinks," "natural cheeses," and the like. For example, fermented milk is defined as "fermented milk" defined in the Ministerial Ordinance on Milk, etc., that is, raw milk, cow's milk, special milk, raw goat's milk, pasteurized goat's milk, raw sheep's milk, ingredient-adjusted milk, low-fat milk, non-fat milk. Milk such as processed milk or milk containing an equivalent or higher non-fat milk solid content is fermented with lactic acid bacteria or yeast to form a solid (hard type), pasty (soft type) or liquid (drink type). This includes, but is not limited to, frozen products. In the fermented milk according to the embodiment of the present invention, the concentration of non-fat milk solids is preferably within a range of, for example, 4.0% by mass or more and 12.0% by mass or less, and 6.0% by mass. % or more and 10.0% by mass or less, and even more preferably 7.0% by mass or more and 9.0% by mass or less. In addition, the concentration of milk fat is preferably in the range of 0.2% by mass or more and 4.0% by mass or less, and preferably in the range of 0.3% by mass or more and 3.0% by mass or less. is more preferable, and even more preferably within the range of 0.4% by mass or more and 2.0% by mass or less.
発酵乳の典型例としては、ヨーグルトが挙げられる。国際連合食糧農業機関（ＦＡＯ）／世界保健機構（ＷＨＯ）で定義されている国際規格にも、「ヨーグルトと称される製品は、Streptococcus thermophilus、Lactobacillus delbrueckii ssp. bulgaricusの両方の菌の乳酸発酵作用により、乳及び脱脂粉乳などの乳製品から作られるもので、最終製品中には前述の２つの菌が多量に生存しているもの」と規定されている。本発明において、「ヨーグルト」とは、前記のＦＡＯ／ＷＨＯの定義するヨーグルトを包含するものである。このヨーグルトには、例えばプレーンヨーグルト、ハードヨーグルト（セットタイプヨーグルト）、ソフトヨーグルト、ドリンクヨーグルトなどが含まれる。本発明では、摂取しやすさの観点から、特にドリンクヨーグルトが好ましい。 A typical example of fermented milk is yogurt. The international standards defined by the Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO) also state that ``Products called yogurt must be produced by the lactic acid fermentation action of both Streptococcus thermophilus and Lactobacillus delbrueckii ssp. bulgaricus. "It is made from dairy products such as milk and skim milk powder, and the two types of bacteria mentioned above are present in large quantities in the final product." In the present invention, "yogurt" includes yogurt as defined by the above-mentioned FAO/WHO. This yogurt includes, for example, plain yogurt, hard yogurt (set type yogurt), soft yogurt, and drink yogurt. In the present invention, drink yogurt is particularly preferred from the viewpoint of ease of ingestion.
また、本発明の実施の形態において、ラクトバチルス ブルガリカスに属する乳酸菌の１日あたりの摂取量は、１０６ｃｆｕ以上であることが好ましく、１０７ｃｆｕ以上であることがより好ましく、１０８ｃｆｕ以上であることがさらに好ましく、１０９ｃｆｕ以上であることが特に好ましい。なお、ラクトバチルス ブルガリカスに属する乳酸菌の１日あたりの摂取量の上限は、特に限定されないが、例えば、１０１２ｃｆｕである。 Further, in an embodiment of the present invention, the daily intake of lactic acid bacteria belonging to Lactobacillus bulgaricus is preferably 10 6 cfu or more, more preferably 10 7 cfu or more, and 10 8 cfu or more. It is more preferably at least 10 9 cfu, particularly preferably at least 10 9 cfu. Note that the upper limit of the daily intake of lactic acid bacteria belonging to Lactobacillus bulgaricus is, for example, 10 12 cfu, although it is not particularly limited.
また、本発明の実施の形態において、菌体外多糖の１日あたりの摂取量は、１００μｇ以上であることが好ましく、５００μｇ以上であることがより好ましく、１．０ｍｇ以上であることがさらに好ましく、２．０ｍｇ以上であることが特に好ましい。なお、菌体外多糖の１日あたりの摂取量の上限は、特に限定されないが、例えば、２００ｍｇであることが好ましく、１００ｍｇであることがより好ましく、７０ｍｇであることがさらに好ましく、３５ｍｇであることがさらに好ましく、３０ｍｇであることがさらに好ましく、８．０ｍｇであることが特に好ましい。 Furthermore, in the embodiment of the present invention, the daily intake of the exopolysaccharide is preferably 100 μg or more, more preferably 500 μg or more, and even more preferably 1.0 mg or more. , 2.0 mg or more is particularly preferred. Note that the upper limit of the daily intake of bacterial exopolysaccharide is not particularly limited, but for example, it is preferably 200 mg, more preferably 100 mg, even more preferably 70 mg, and 35 mg. More preferably, it is 30 mg, and particularly preferably 8.0 mg.
本発明の実施の形態に係る高負荷運動体調不良化緩和等用組成物を１回の摂取に適切な量で１個包装の形態とすることにより、同組成物を適切かつ手軽に摂取することができることになり、使用性の面から好ましい。１回の摂取に適切な量は、高負荷運動の程度や体調の不良化の程度などによると共に個人差やばらつきがあるものの、同組成物が、例えば、無脂乳固形分が８．０質量％である発酵乳である場合には、１回あたりで１０ｍＬ以上１０００ｍＬ以下の範囲内であることが好ましく、３０ｍＬ以上５００ｍＬ以下の範囲内であることがより好ましく、５０ｍＬ以上２００ｍＬ以下の範囲内であることがさらに好ましく、８０ｍＬ以上１２０ｍＬ以下であることが好ましい。あるいは、１回あたりで１０ｇ以上１０００ｇ以下の範囲内であることが好ましく、３０ｇ以上５００ｇ以下の範囲内であることが好ましく、５０ｇ以上２００ｇ以下の範囲内であることが好ましく、８０ｇ以上１５０ｇ以下の範囲内であることがより好ましく、１００ｇ以上１２０ｇ以下の範囲内であることがさらに好ましい。 By packaging the composition for relieving physical condition due to high-intensity exercise according to the embodiment of the present invention in a single package with an appropriate amount for one intake, the composition can be appropriately and easily ingested. This is preferable from the viewpoint of usability. Although the appropriate amount for one intake varies depending on the degree of high-intensity exercise and the degree of poor physical condition, and varies among individuals, for example, if the same composition has non-fat milk solids of 8.0 mass %, it is preferably within the range of 10 mL or more and 1000 mL or less, more preferably within the range of 30 mL or more and 500 mL or less, and within the range of 50 mL or more and 200 mL or less. More preferably, the amount is 80 mL or more and 120 mL or less. Alternatively, it is preferably within the range of 10 g to 1000 g, preferably within the range of 30 g to 500 g, preferably within the range of 50 g to 200 g, and preferably within the range of 80 g to 150 g. It is more preferably within the range, and even more preferably within the range of 100 g or more and 120 g or less.
本発明の実施の形態では、「１個包装の形態」はあらゆる形態、例えば、蓋付きの容器、キャップ付きのボトル、個袋、パウチ、チューブなどの一般的な包装形態が包含される。本発明の実施の形態では、各個包装、または複数の個包装を含む包装に、本発明の実施の形態に係る高負荷運動体調不良化緩和等用組成物の用途、効能、摂取方法などの説明を記載すること、および／または、その説明を記載した物等を封入等すること、および／または、別途パンフレットなど、その説明を記載した物等を掲示することなどにより、その用途を明確にすることができる。 In the embodiment of the present invention, the "single packaging form" includes all forms, for example, general packaging forms such as containers with lids, bottles with caps, individual bags, pouches, and tubes. In the embodiment of the present invention, each individual package or a package including a plurality of individual packages includes explanations such as the use, efficacy, and ingestion method of the composition for alleviating physical condition caused by high-intensity exercise according to the embodiment of the present invention. Clarify its purpose by stating the following, and/or enclosing an item with the explanation, and/or posting a separate pamphlet or other item with the explanation. be able to.
本発明の実施の形態に係る高負荷運動体調不良化緩和等用組成物は、高負荷運動による体調の不良化緩和効果、抑制効果、予防効果を高める観点から、３日間以上継続して摂取することが好ましく、５日間以上継続して摂取することが好ましく、１週間以上継続して摂取することが好ましく、２週間以上継続して摂取することが好ましく、４週間以上継続して摂取することが好ましく、６週間以上継続して摂取することがより好ましく、８週間以上継続して摂取することがさらに好ましく、１０週間以上継続して摂取することがさらに好ましく、１２週間以上継続して摂取することがさらに好ましく、２４週間以上継続して摂取することがさらに好ましく、３６週間以上継続して摂取することが特に好ましい。なお、同組成物が発酵乳である場合、その組成物は十分な食経験があり安全に摂取することができるため、摂取期間の上限は特に制限されず、永久的に継続することが可能であるが、強いて上限を設けるならば、例えば６０週間以下である。なお、この上限は、高負荷運動の程度や体調の不良化の程度などにより、例えば、１２０週間以下としてもよいし、１００週間以下としてもよいし、８０週間以下としてもよい。 The composition for alleviating poor physical condition caused by high-intensity exercise according to the embodiment of the present invention is taken continuously for three days or more in order to enhance the effect of alleviating, suppressing, and preventing poor physical condition caused by high-intensity exercise. It is preferable to take it continuously for 5 days or more, it is preferable to take it continuously for 1 week or more, it is preferable to take it continuously for 2 weeks or more, and it is preferable to take it continuously for 4 weeks or more. Preferably, it is preferably ingested for 6 weeks or more, more preferably for 8 weeks or more, even more preferably for 10 weeks or more, and even more preferably for 12 weeks or more. is more preferable, it is even more preferable to take it continuously for 24 weeks or more, and it is particularly preferable to take it continuously for 36 weeks or more. In addition, if the composition is fermented milk, there is no particular restriction on the upper limit of the intake period, and it can be continued indefinitely, as there is sufficient experience with the composition and it can be safely ingested. However, if we were to force an upper limit, it would be, for example, 60 weeks or less. Note that this upper limit may be, for example, 120 weeks or less, 100 weeks or less, or 80 weeks or less depending on the degree of high-intensity exercise and the degree of deterioration of physical condition.
本発明の実施の形態に係る高負荷運動体調不良化緩和等用組成物は、経口摂取されるのが好ましい。 The composition for alleviating poor physical condition due to high-intensity exercise according to the embodiment of the present invention is preferably ingested orally.
ところで、本発明の実施の形態に係る高負荷運動体調不良化緩和等用組成物に、その用途、効能、機能、有効成分の種類、使用方法などの説明を表示することが好ましい。ここにいう「表示」には、需要者に対して上記効果の説明を知らしめるための全ての表示が含まれる。この表示は、上述の表示内容を想起・類推させ得るような表示であればよく、表示の目的、表示の内容、表示する対象物・媒体などの如何に拘わらない全てのあらゆる表示を含み得る。例えば、製品の包装・容器に上記説明を表示すること、製品に関する広告・価格表もしくは取引書類に上記説明を表示して展示もしくは頒布すること、またはこれらを内容とする情報を電磁気的（インターネットなど）方法により提供することが挙げられる。 Incidentally, it is preferable that the composition for alleviating deterioration caused by high-intensity exercise according to the embodiment of the present invention be provided with an explanation of its use, efficacy, function, type of active ingredient, method of use, etc. The "display" referred to here includes all displays for informing consumers of the explanation of the above-mentioned effects. This display may be any display that can be recalled or analogized to the above-mentioned display content, and may include any and all displays regardless of the purpose of the display, the content of the display, the object or medium to be displayed, etc. For example, displaying the above explanation on the product's packaging/container, displaying or distributing the above explanation on product-related advertisements, price lists, or transaction documents, or distributing information containing the above by electromagnetic means (such as the Internet). ) method.
本発明の実施の形態に係る高負荷運動体調不良化緩和等用組成物を包装してなる製品には、例えば、「高負荷運動による体調の不良化を緩和する」、「高負荷運動による体調の不良化を抑制する」、「高負荷運動による体調の不良化を予防する」、「高負荷運動による体調の不良化の緩和用」、「高負荷運動による体調の不良化の抑制用」、「高負荷運動による体調の不良化の予防用」等との表示が付されることが好ましい。 Products packaged with compositions for alleviating poor physical condition due to high-intensity exercise according to embodiments of the present invention include, for example, "alleviating poor physical condition due to high-intensity exercise," "alleviating poor physical condition due to high-intensity exercise," etc. ``Suppressing deterioration of physical condition due to high-intensity exercise'', ``Preventing deterioration of physical condition due to high-intensity exercise'', ``Reducing deterioration of physical condition due to high-intensity exercise'', ``Suppressing deterioration of physical condition due to high-intensity exercise'', It is preferable that a label such as "For prevention of poor physical condition due to high-intensity exercise" be attached.
なお、以上のような表示を行うために使用する文言は、上述の例に限定されず、そのような意味と同義である文言であってもかまわない。そのような文言としては、例えば、需要者に対して、「高負荷運動を行った後も体調（コンディション）を良好に保つ」、「高負荷運動を行った後の体調（コンディション）の回復を促進する」、「高負荷運動を行った後も、高負荷運動前の体調（コンディション）を維持する」、「過剰な（激しい）運動による筋肉量の減少、筋力の低下、筋肉分解、筋疲労、筋炎、筋肉痛および筋損傷を予防する」、「ハードな運動後のリカバーをサポートする」、「ハードな運動後の体調（コンディション）の回復をサポートする」、「激しい運動を継続したい方のカラダ全体のコンディショニングをサポート」、「アスリートのコンディショニングをサポート」、「酷使したカラダのリカバリーのために」、「酷使したカラダの体調（コンディション）の回復のために」等の種々の文言が許容され得る。 Note that the wording used to make the above display is not limited to the above-mentioned example, and may be a wording that is synonymous with such a meaning. Examples of such language include, for example, asking consumers to ``maintain good physical condition even after performing high-intensity exercise,'' and ``recovering physical condition after performing high-intensity exercise.'' ``Promote high-intensity exercise'', ``Maintain the physical condition before high-intensity exercise even after performing high-intensity exercise'', ``Decrease in muscle mass, decrease in muscle strength, muscle decomposition, muscle fatigue due to excessive (intense) exercise'' , "Preventing myositis, muscle pain, and muscle damage", "Supporting recovery after hard exercise", "Supporting recovery of physical condition after hard exercise", "For those who want to continue intense exercise" Various phrases are acceptable, such as "Supports the conditioning of the entire body," "Supports the conditioning of athletes," "For the recovery of an overworked body," and "For recovery of the physical condition of an overworked body." obtain.
なお、上述の高負荷運動体調不良化緩和等用組成物は、特別用途食品、総合栄養食品、栄養補助食品、特定保健用食品、機能性表示食品、加工食品等の形態にすることもできる。また、同組成物や、ラクトバチルス ブルガリカスに属する乳酸菌、菌体外多糖は、ドリンクヨーグルト以外の飲料や流動食等の組成物に配合することもできる。 The above-mentioned composition for alleviating poor physical condition due to high-intensity exercise can also be in the form of a food for special use, a comprehensive nutritional food, a nutritional supplement, a food for specified health uses, a food with functional claims, a processed food, and the like. Further, the same composition, lactic acid bacteria belonging to Lactobacillus bulgaricus, and exopolysaccharides can also be blended into compositions such as drinks other than yogurt drinks and liquid foods.
以下、実施例および比較例に基づいて、本発明をより具体的に説明する。なお、この実施例は、本発明を限定するものではない。 Hereinafter, the present invention will be explained more specifically based on Examples and Comparative Examples. Note that this example does not limit the present invention.
－試験飲料－
ａ）株式会社明治製の明治プロビオヨーグルトＲ－１ドリンクタイプ（ラクトバチルス デルブルエッキー 亜種 ブルガリクス ＯＬＬ１０７３Ｒ－１（ＦＥＲＭ ＢＰ－１０７４１）で乳を発酵して得られたドリングヨーグルト、および、ｂ）プラセボとしての酸性乳飲料を用いて以下の試験を実施した。以下、ドリンクヨーグルトおよび酸性乳飲料を併せて試験飲料と称する場合がある。
-Test drink-
a) Meiji Probio Yogurt R-1 drink type manufactured by Meiji Co., Ltd. (drinking yogurt obtained by fermenting milk with Lactobacillus delbrueckii subspecies bulgaricus OLL1073R-1 (FERM BP-10741), and b) The following test was conducted using an acidic milk drink as a placebo. Hereinafter, the drink yogurt and the acidic milk drink may be collectively referred to as the test drink.
なお、前者のドリンクヨーグルトは、生乳、脱脂粉乳、クリーム、液糖、ペクチン、砂糖、ステビア、乳酸、香料を所定の配合比率で配合したものを、Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1とStreptococus thermophilus OLS3059で醗酵して調製した。なお、このドリンクヨーグルトは２００９年の発売開始以降十分な販売実績を有しており、過去において本製品が原因と考えられる重篤な副作用が報告されたことはない。一方、後者の酸性乳飲料は、脱脂粉乳、乳タンパク、バター、液糖、ペクチン、砂糖、ステビア、乳酸、香料を所定の配合比率で配合して調製した。また、この酸性乳飲料は、ドリンクヨーグルトと同等の風味、物性、酸度とした。 The former drink yogurt is made by blending raw milk, skim milk powder, cream, liquid sugar, pectin, sugar, stevia, lactic acid, and flavorings in a predetermined ratio, and contains Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 and Streptococcus thermophilus OLS3059. It was prepared by fermentation. This drink yogurt has had a good sales record since its launch in 2009, and there have been no reports of serious side effects that could be caused by this product in the past. On the other hand, the latter acidic milk drink was prepared by blending skim milk powder, milk protein, butter, liquid sugar, pectin, sugar, stevia, lactic acid, and flavoring at a predetermined blending ratio. In addition, this acidic milk drink had the same flavor, physical properties, and acidity as drink yogurt.
なお、ドリンクヨーグルトおよび酸性乳飲料は、食品衛生法「食品、添加物等の規格基準」、「乳等省令」に準じて定められた品質規格を満たすように調製された。以下にそれらの品質規格を示す。 The yogurt drink and the acidic milk drink were prepared to meet the quality standards established in accordance with the Food Sanitation Law "Standards for Foods, Additives, etc." and the "Milk Ministerial Ordinance." The quality standards are shown below.
（ドリンクヨーグルトの品質規格）
・ｐＨ：４．２０±０．２０
・酸度：０．７６～０．８５
・総乳酸菌数：２０×１０７ｃｆｕ／ｍＬ以上
・OLL1073R-1株菌数：７×１０７ｃｆｕ／ｍＬ以上
・大腸菌群：陰性
・性状（外観、風味など）：良好
(Quality standards for drink yogurt)
・pH: 4.20±0.20
・Acidity: 0.76-0.85
・Total lactic acid bacteria count: 20×10 7 cfu/mL or more ・OLL1073R-1 strain bacterial count: 7×10 7 cfu/mL or more ・Coliform group: Negative ・Properties (appearance, flavor, etc.): Good
（酸性乳飲料）
・ｐＨ：４．２０±０．２０
・酸度：０．７６～０．８５
・総乳酸菌数：－
・OLL1073R-1株菌数：－
・大腸菌群：陰性
・性状（外観、風味など）：良好
(acidic milk drink)
・pH: 4.20±0.20
・Acidity: 0.76-0.85
・Total lactic acid bacteria count: -
・OLL1073R-1 strain number: -
・Coliform group: Negative ・Characteristics (appearance, flavor, etc.): Good
上述のドリンクヨーグルトおよび酸性乳飲料、ともに無地の容器に充填した。その内容量はともに１１２ｍＬであった。いずれの試験飲料も製造後、被験者の下に届くまでの間４℃で冷蔵保存された。 Both the yogurt drink and the acidic milk drink described above were filled into plain containers. The contents of both were 112 mL. After production, all test drinks were stored refrigerated at 4°C until they were delivered to the subjects.
－試験－
上記ドリングヨーグルト摂取群とプラセボ摂取群によるランダム化プラセボ対照二重盲検並行群間比較試験を実施した。なお、本試験は明治臨床試験審査委員会の審査承認を得た試験計画書に基づいて行った。試験実施においては、ヘルシンキ宣言の精神にのっとり、試験の目的、方法、予想される副作用等について全ての被験者に十分に事前説明を行った。
-test-
A randomized, placebo-controlled, double-blind, parallel-group comparison study was conducted between the drinking yogurt intake group and the placebo intake group. This study was conducted based on a study protocol approved by the Meiji Clinical Trials Review Committee. In conducting the study, in accordance with the spirit of the Declaration of Helsinki, all subjects were fully briefed on the purpose, method, expected side effects, etc. of the study.
以下、この試験条件について詳述する。
（１）被験者
Ｘ大学の陸上部に所属する男子長距離選手１８名と男子投擲選手１３名を被験者とした。被験者の選択基準および除外基準は、以下の通りであった。
＜選択基準＞
ａ）１８歳以上２５歳以下の健常者
ｂ）Ｘ大学の陸上部に所属する大学生
ｃ）事前に本試験の説明を受け、その内容を理解して趣旨に賛同でき、文書同意が得られる者（未成年者は親の文書同意が得られる者）
＜除外基準＞
ａ）他の臨床試験に参加中の者
ｂ）重い心疾患・腎疾患・肝疾患・呼吸器疾患・循環器疾患、食物アレルギー疾患等を患っている者
ｃ）乳糖不耐症の者
ｄ）その他試験統括責任者および試験責任医師が不適当と判断した者
The test conditions will be explained in detail below.
(1) Subjects The subjects were 18 male long-distance athletes and 13 male throwers who belong to the track and field club at University X. Subject selection and exclusion criteria were as follows.
<Selection criteria>
a) Healthy individuals between the ages of 18 and 25 b) University students who belong to the track and field club of University (Minors are those who can obtain written consent from their parents)
<Exclusion criteria>
a) Persons participating in other clinical trials b) Persons suffering from severe heart disease, kidney disease, liver disease, respiratory disease, circulatory system disease, food allergy disease, etc. c) Persons with lactose intolerance d) Any other person deemed inappropriate by the study supervisor and the study director.
（２）群割付
本試験に関与しない割付け責任者が、試験開始時における被験者の年齢、身長、体重、競技能力を層別因子として、競技毎に被験者を、ドリングヨーグルト摂取群（以下「ＤＹ群」と称する場合がある）とプラセボ摂取群（以下「ＰＣ群」と称する場合がある）の２群に割り付けた。各群の人数、年齢、体重および身長の平均値および標準偏差は以下の表１に示されている。また、被験者らの群割付後、両群で血中のクレアチンキナーゼ（ＣＫ）の濃度に有意な差がないことを確認した（血中のクレアチンキナーゼ（ＣＫ）の濃度の測定方法等は以下に示される通りである。）。なお、群割付表は割付責任者が封緘し、群割付表開封まで密封保管した。
(2) Group Assignment The person in charge of assignment who is not involved in this study will assign subjects to the Drinking Yogurt intake group (hereinafter "DY group") for each competition, using the age, height, weight, and athletic ability of the subjects at the start of the study as stratification factors. The subjects were divided into two groups: a group receiving a placebo (hereinafter sometimes referred to as the "PC group") and a group receiving a placebo (sometimes referred to as the "PC group"). The average values and standard deviations of the number, age, weight, and height of each group are shown in Table 1 below. Furthermore, after assigning the subjects to groups, it was confirmed that there was no significant difference in the concentration of creatine kinase (CK) in the blood between the two groups (the method for measuring the concentration of creatine kinase (CK) in the blood is described below) (as shown). The group allocation table was sealed by the person responsible for allocation and kept sealed until the group allocation table was opened.
（３）試験詳細
上述の通り、試験はランダム化プラセボ対照二重盲検並行群間比較法で実施した。
試験飲料の摂取期間を２週間とした。また、そのうちの１週間を合宿期間とした。試験飲料の摂取期間中、１日２本、試験飲料を摂取することを義務付けた。なお、試験飲料の摂取タイミングは特に指定しなかった。試験飲料の摂取開始日、摂取開始１週後に当たる日（中間日）、摂取終了日に被験者全員に対して採血を行って、その血液の成分分析を行った。なお、試験期間中、食事制限は一切行わず、他のヨーグルトや乳製品を摂取した場合には日誌に記載するように指導した。また、抗生物質など医薬品、サプリメントを服用した際にも日誌に記載するように指導した。
(3) Study details As mentioned above, the study was conducted using a randomized, placebo-controlled, double-blind, parallel-group comparison method.
The test drink was consumed for two weeks. Additionally, one week of the training camp period was designated as a training camp period. During the intake period of the test drink, subjects were required to consume the test drink twice a day. Note that the timing of ingestion of the test drink was not specified. Blood was collected from all subjects on the day they started taking the test drink, the day one week after the start of taking it (intermediate day), and the day they finished taking it, and the blood components were analyzed. During the test period, there were no dietary restrictions, and subjects were instructed to record in their diaries if they ingested other yogurt or dairy products. They were also instructed to record in their diaries when they took medicines such as antibiotics or supplements.
（４）血液検査
（４－１）検査方法の詳細
被験者らから採取された血液を株式会社エスアールエルに提供してその血液の血液生化学的検査および特殊検査を行ってもらった。なお、血液生化学的検査では総タンパク質およびクレアチンキナーゼの血中濃度が測定され、特殊検査では、アミノ酸の血中濃度が測定された。
(4) Blood test (4-1) Details of test method Blood collected from the subjects was provided to SRL Co., Ltd., and the blood was subjected to blood biochemical tests and special tests. Blood biochemical tests measured blood concentrations of total protein and creatine kinase, and special tests measured blood amino acid concentrations.
（４－２）統計処理
すべての測定値すなわち血中濃度は平均値±標準偏差で示した。ＤＹ群－ＰＣ群間の比較は、二元配置反復測定分散分析に基づいて行われた。なお、各測定点においてBonferroniの多重比較検定を行った。各試験飲料群における試験飲料摂取前の血中濃度に対する試験飲料摂取後の血中濃度の比較はBonferroniの多重比較検定を行った。なお、全ての検定は両側検定とされ、その有意水準は５％とした。各表において、群間交互作用および群間の検定結果は、各表の右側にそれぞれ数値で示した。開始地点(０週)と比較した測定値の検定結果（群内の有意差）には、それぞれＰ＜０．０５である場合は＊の印を、Ｐ＜０．０１の場合は＊＊の印を、各測定値（数字）の右上に示した。
(4-2) Statistical processing All measured values, that is, blood concentrations, were expressed as mean ± standard deviation. Comparisons between the DY group and the PC group were made based on a two-way repeated measures analysis of variance. In addition, Bonferroni's multiple comparison test was performed at each measurement point. Bonferroni's multiple comparison test was performed to compare the blood concentration before and after ingestion of the test drink in each test drink group. All tests were two-tailed, and the significance level was set at 5%. In each table, the intergroup interaction and the test results between groups are shown numerically on the right side of each table. Test results (significant differences within groups) of measured values compared with the starting point (week 0) are marked with * if P < 0.05, and with ** if P < 0.01. A mark is shown on the upper right of each measured value (number).
（４－３）検査結果
血中総タンパク質濃度および血中クレアチンキナーゼ濃度の測定結果を表２に示す。ＰＣ群では酸性乳飲料の摂取前に比べて摂取２週後の血中総タンパク質濃度が有意に減少したが、ＤＹ群ではドリンクヨーグルト摂取前後で血中総タンパク質濃度はほとんど変動しなかった。また、ＰＣ群では酸性乳飲料の摂取前に比べて摂取１週後に血中クレアチンキナーゼ濃度が有意に上昇したが、ＤＹ群ではドリンクヨーグルト摂取前後で血中クレアチンキナーゼ濃度はほとんど変動しなかった。また、摂取二週後、ＤＹ群の血中クレアチンキナーゼ濃度およびＣＹ群の血中クレアチンキナーゼ濃度が同等になっているが、これは、自己修復機能より骨格筋が修復された結果であると推察される。
(4-3) Test results Table 2 shows the measurement results of blood total protein concentration and blood creatine kinase concentration. In the PC group, the blood total protein concentration decreased significantly two weeks after ingesting the acidic milk drink compared to before ingestion, but in the DY group, the blood total protein concentration hardly changed before and after ingesting the yogurt drink. In addition, in the PC group, the blood creatine kinase concentration increased significantly one week after ingesting the acidic milk drink compared to before ingesting it, whereas in the DY group, the blood creatine kinase concentration did not change much before and after ingesting the yogurt drink. Furthermore, two weeks after intake, the blood creatine kinase concentrations in the DY group and the CY group were similar, which is presumed to be the result of skeletal muscle repair due to self-repair function. be done.
血中のアミノ酸濃度の測定結果を表３に示す。総アミノ酸、必須アミノ酸および分岐鎖アミノ酸の血中濃度は、ＰＣ群では酸性乳飲料の摂取前に比べて摂取後に有意に減少したが、ＤＹ群ではドリンクヨーグルト摂取前後でほとんど変動しなかった。分岐鎖アミノ酸の中でバリンおよびイソロイシンの血中濃度は、ＰＣ群では酸性乳飲料の摂取前に比べて摂取後に有意に減少したが、ＤＹ群ではドリンクヨーグルト摂取前後でほとんど変動しなかった。メチオニン、チロシン、リジンの血中濃度は、ＤＹ群においてドリンクヨーグルト摂取２週後でＰＣ群に比べて有意に高値であった。また、メチオニン、フェニルアラニン、スレオニン、チロシン、オルニチンおよびシトルリンはＰＣ群でのみ摂取前に比べて摂取２週後に有意に低値を示し、ＤＹ群では変動しなかった。オルニチン、シトルリン、フェニルアラニンおよびスレオニンの血中濃度は、ＰＣ群でのみ酸性乳飲料の摂取前に比べて摂取２週後に有意に減少したが、ＤＹ群ではドリンクヨーグルト摂取前後でほとんど変動しなかった。 Table 3 shows the measurement results of blood amino acid concentrations. The blood concentrations of total amino acids, essential amino acids, and branched-chain amino acids decreased significantly after ingesting the acidic milk drink in the PC group compared to before ingesting it, but there was almost no change before and after ingesting the yogurt drink in the DY group. Among the branched-chain amino acids, the blood concentrations of valine and isoleucine decreased significantly after ingesting the acidic milk drink in the PC group compared to before ingesting it, whereas in the DY group there was almost no change before and after ingesting the yogurt drink. Blood concentrations of methionine, tyrosine, and lysine were significantly higher in the DY group than in the PC group two weeks after ingesting the yogurt drink. Furthermore, methionine, phenylalanine, threonine, tyrosine, ornithine, and citrulline showed significantly lower values only in the PC group after 2 weeks of intake compared to before intake, and did not change in the DY group. The blood concentrations of ornithine, citrulline, phenylalanine, and threonine decreased significantly only in the PC group two weeks after ingesting the acidic milk drink compared to before ingesting it, but in the DY group there was almost no change before and after ingesting the yogurt drink.
なお、本試験期間中に重篤な有害事象や試験食品摂取との因果関係が認められる有害事象は発生しなかった。また、自他覚症状において、問題となる所見は認められなかった。 Furthermore, during the study period, no serious adverse events or adverse events with a causal relationship to test food intake occurred. Furthermore, no problematic findings were observed regarding subjective and objective symptoms.
（５）考察
上述の通り、血中総タンパク質濃度はＰＣ群では酸性乳飲料の摂取前に比べて摂取２週後に有意に減少したが、ＤＹ群ではドリンクヨーグルト摂取前後でほとんど変動しなかった。また、血中クレアチンキナーゼ濃度はＰＣ群では酸性乳飲料の摂取１週後に有意に上昇したが、ＤＹ群ではドリンクヨーグルト摂取前後でほとんど変動しなかった。一般的に、激しい運動に伴う食欲不振や身体コンディションの悪化により、血中総タンパク質濃度は低下し、血中クレアチンキナーゼ濃度は急激に上昇する。したがって、ＤＹ群ではドリンクヨーグルトの摂取により、激しい運動に伴う栄養状態の悪化や、筋損傷および肝機能の低下が抑制され、正常な状態が維持されたと考えられる。
(5) Discussion As mentioned above, in the PC group, the blood total protein concentration decreased significantly two weeks after ingesting the acidic milk drink compared to before ingesting it, but in the DY group, there was almost no change before and after ingesting the yogurt drink. Furthermore, the blood creatine kinase concentration significantly increased in the PC group one week after ingesting the acidic milk drink, but in the DY group there was almost no change before and after ingesting the yogurt drink. Generally, due to loss of appetite and deterioration of physical condition due to intense exercise, total blood protein concentration decreases and blood creatine kinase concentration rapidly increases. Therefore, it is considered that in the DY group, the intake of drinkable yogurt suppressed the deterioration of nutritional status, muscle damage, and decline in liver function due to intense exercise, and maintained a normal state.
ＰＣ群では酸性乳飲料の摂取前に比べて摂取後に多くのアミノ酸の血中濃度が低下したが、ＤＹ群ではドリンクヨーグルト摂取前後で変動せず恒常性が維持された。 In the PC group, the blood concentrations of many amino acids decreased after ingesting the acidic milk drink compared to before, but in the DY group, there was no change before and after ingesting the yogurt drink, and homeostasis was maintained.
また、上述の通り、多くのアミノ酸の中でも、スポーツコンディションの維持に重要である必須アミノ酸、そのなかでもバリンやイソロイシン等の分岐鎖アミノ酸の血中濃度の低下がＤＹ群で抑制され、メチオニン、チロシンおよびリジンの血中濃度は試験飲料の摂取２週後にプラセボ群に比べてＤＹ群で有意に高値を示した。ＰＣ群で見られた総アミノ酸、必須アミノ酸、分岐鎖アミノ酸の血中濃度の低下は、運動負荷による体内の代謝異常を示唆していると推測される。一方、ＤＹ群ではドリンクヨーグルトの摂取前後で血中アミノ酸濃度がほとんど変動しなかったことから、激しい運動に伴う体調の悪化を抑制したものと推察される。 In addition, as mentioned above, among the many amino acids, the decrease in the blood concentration of essential amino acids, which are important for maintaining sports condition, and branched chain amino acids such as valine and isoleucine, was suppressed in the DY group, and methionine, tyrosine, etc. Two weeks after ingesting the test drink, the blood concentration of lysine was significantly higher in the DY group than in the placebo group. The decrease in blood concentrations of total amino acids, essential amino acids, and branched-chain amino acids observed in the PC group is presumed to suggest metabolic abnormalities in the body due to exercise load. On the other hand, in the DY group, there was almost no change in blood amino acid concentration before and after ingesting the yogurt drink, suggesting that it suppressed the deterioration of physical condition associated with intense exercise.
以上の結果から、激しい運動に伴いアミノ酸代謝が一時的に異常をきたしたが、ドリンクヨーグルトの摂取により激しい運動に伴う一時的な代謝機能や栄養状態の悪化が抑制され、筋合成の恒常性も維持されたと推察される。 From the above results, amino acid metabolism was temporarily abnormal due to intense exercise, but drinking yogurt suppressed the temporary deterioration of metabolic function and nutritional status caused by intense exercise, and also maintained the homeostasis of muscle synthesis. It is presumed that it has been maintained.
（６）結論
ラクトバチルス デルブルエッキー 亜種 ブルガリクス ＯＬＬ１０７３Ｒ－１（ＦＥＲＭ ＢＰ－１０７４１）で乳を発酵して得られたドリンクヨーグルトの摂取により、激しい運動に伴うアミノ酸代謝異常を抑制し血中アミノ酸濃度を維持することで、筋合成の恒常性を保ち身体状態を正常に維持することが示唆された。
(6) Conclusion Ingestion of drink yogurt obtained by fermenting milk with Lactobacillus delbrueckii subspecies bulgaricus OLL1073R-1 (FERM BP-10741) suppresses amino acid metabolic abnormalities associated with intense exercise and improves blood amino acid levels. It was suggested that maintaining the concentration maintains the homeostasis of muscle synthesis and maintains a normal physical condition.
本発明に係る高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物は、非医薬系の組成物であって、高負荷運動による体調の不良化を緩和したり、抑制したり、予防したりすることができる。 The composition for alleviating, suppressing, or preventing deterioration in physical condition due to high-intensity exercise according to the present invention is a non-pharmaceutical composition, and is a composition for alleviating, suppressing, or preventing deterioration in physical condition due to high-intensity exercise. can be prevented or prevented.
ＦＥＲＭ ＢＰ－１０７４１
ＦＥＲＭ ＢＰ－１０７４０
FERM BP-10741
FERM BP-10740
Claims (15)
請求項１に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 The composition for alleviating, suppressing, or preventing deterioration in physical condition due to high-intensity exercise according to claim 1, wherein the deterioration in physical condition is deterioration in physical condition.
請求項２に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 The composition for alleviating, suppressing, or preventing deterioration in physical condition due to high-intensity exercise according to claim 2, wherein the deterioration in physical condition is deterioration in nutritional status.
請求項３に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 4. The use for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise according to claim 3, wherein the deterioration of nutritional status is at least one of a decrease in blood protein concentration and a decrease in blood amino acid concentration. Composition for use.
請求項２に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 3. The deterioration in physical condition due to high-load exercise according to claim 2, wherein the deterioration in physical condition is at least one of a decrease in muscle mass, a decrease in muscle strength, muscle decomposition, muscle fatigue, myositis, muscle pain, and muscle damage. Compositions for the palliation, suppression or prophylaxis of.
請求項１に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 The composition for alleviating, suppressing, or preventing deterioration in physical condition due to high-intensity exercise according to claim 1, wherein the deterioration in physical condition is deterioration in psychological state.
請求項６に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 The composition for alleviating, suppressing, or preventing deterioration in physical condition due to high-intensity exercise according to claim 6, wherein the deterioration in psychological state is at least one of insomnia, decreased concentration, and onset of depression. .
請求項１から７のいずれか１項に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 The lactic acid bacterium belonging to Lactobacillus bulgaricus is a lactic acid bacterium belonging to the Lactobacillus bulgaricus delbruecki species, for alleviating or suppressing deterioration of physical condition due to high-intensity exercise according to any one of claims 1 to 7. or prophylactic compositions.
請求項８に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 Alleviation of poor physical condition due to high-intensity exercise according to claim 8, wherein the lactic acid bacterium belonging to the Lactobacillus bulgaricus delbrueckii species is Lactobacillus bulgaricus subspecies delbrueckii OLL1073R-1 (FERM BP-10741). therapeutic, suppressive or prophylactic compositions.
請求項１から７のいずれか１項に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 The composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise according to any one of claims 1 to 7, wherein the composition is a fermented food.
請求項１０に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 The composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise according to claim 10, wherein the fermented food is fermented milk.
請求項１０に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 The composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise according to claim 10, wherein the fermented food is fermented by lactic acid bacteria belonging to at least Lactobacillus bulgaricus.
請求項１２に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 The composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise according to claim 12, wherein the lactic acid bacteria belonging to Lactobacillus bulgaricus are lactic acid bacteria belonging to Lactobacillus bulgaricus delbruecki species.
請求項１３に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 The method of alleviating poor physical condition due to high-intensity exercise according to claim 13, wherein the lactic acid bacteria belonging to the species Lactobacillus bulgaricus delbrueckii is Lactobacillus delbrueckii subspecies bulgaricus OLL1073R-1 (FERM BP-10741). therapeutic, suppressive or prophylactic compositions.
請求項１から７のいずれか１項に記載の高負荷運動による体調の不良化の緩和用、抑制用または予防用組成物。 The composition for alleviating, suppressing, or preventing deterioration of physical condition due to high-intensity exercise according to any one of claims 1 to 7, wherein the active ingredient is fermented milk.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022109673A JP2024008104A (en) | 2022-07-07 | 2022-07-07 | Composition for alleviation, inhibition, or prevention of getting out of shape due to high-intensity exercise |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022109673A JP2024008104A (en) | 2022-07-07 | 2022-07-07 | Composition for alleviation, inhibition, or prevention of getting out of shape due to high-intensity exercise |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2024008104A true JP2024008104A (en) | 2024-01-19 |
Family
ID=89544358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022109673A Pending JP2024008104A (en) | 2022-07-07 | 2022-07-07 | Composition for alleviation, inhibition, or prevention of getting out of shape due to high-intensity exercise |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2024008104A (en) |
-
2022
- 2022-07-07 JP JP2022109673A patent/JP2024008104A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kemsawasd et al. | Survival of immobilized probiotics in chocolate during storage and with an in vitro gastrointestinal model | |
| US9439933B2 (en) | Skin properties improving agent for oral administration | |
| Homayouni et al. | Functional dairy probiotic food development: trends, concepts, and products | |
| Hemsworth et al. | The development of micronutrient supplemented probiotic yogurt for people living with HIV: Laboratory testing and sensory evaluation | |
| US20120015070A1 (en) | Fermented milk beverage | |
| JP6046490B2 (en) | Sterilized and fermented dairy products and methods for preparing such products | |
| US11638431B2 (en) | Fermented milk and polysaccharide with cancerous cachexia inhibitory effect | |
| JP2023096136A (en) | Composition for improving work performance | |
| JP2024008104A (en) | Composition for alleviation, inhibition, or prevention of getting out of shape due to high-intensity exercise | |
| CN110403014A (en) | A kind of nutrient powder and the preparation method and application thereof of energy appetite-suppressing | |
| Zhang et al. | From the past to the future: Fermented milks and their health effects against human diseases | |
| JP7369992B2 (en) | Fermented milk for improving autonomic nervous function | |
| JP2019081733A5 (en) | ||
| WO2018030388A9 (en) | Citrulline-containing fermented milk and method for producing same | |
| JP7049397B2 (en) | Composition for suppressing or improving depression | |
| JP2020184906A5 (en) | ||
| RU2815833C2 (en) | Composition for relieving anxiety and/or stress | |
| TW201808120A (en) | Agent for improving physical fitness | |
| JP2020018273A (en) | Composition for reducing fatigue from high-intensity exercise or recovering therefrom | |
| Wojciechowska-Alwin et al. | Influence of natural dairy probiotics on health | |
| RU2580034C1 (en) | Method of producing fermented milk bioproduct | |
| RU2575103C2 (en) | Cultured milk product | |
| Akbarova et al. | COMPARATIVE ANALYSIS OF THE USE OF NATURAL PROBIOTICS AND MEDICINES WITH THEIR CONTENT ON THE BASIS OF AN EXPERIMENT WITH STUDENTS OF KEMEROVO STATE UNIVERSITY | |
| Fayed et al. | Studies on the production of synbiotic yoghurt | |
| WO2020036229A1 (en) | Lactic acid bacterium, agent for increasing blood iron, and agent for ameliorating anemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220707 |